Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Molecular MRD as a prognostic marker for AML patients with mutated CEBPA

Peter Valk • 4 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia

Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, highlights measurable residual disease (MRD) as a prognostic marker for some patients with CEBPA-mutated acute myeloid leukemia (AML). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Peter Valk

Introducing molecular diagnostics to improve leukemia care in developing countries
2:06
Introducing molecular diagnostics to improve leukemia care in developing countries
Peter Valk • 4 Sep 2024
Future considerations for MRD in AML
1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
Distinguishing between de novo AML and secondary AML using mutational signatures
2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
3:22
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
Peter Valk • 29 Sep 2022

Related Videos

Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals